September 30, 2019

OICR Annual Report 2018/19

We are pleased to present the Ontario Institute for Cancer Research (OICR) Annual Report for 2018/19.

Translating cancer research means bringing the best research discoveries to patients, and it’s at the heart of the work we do. OICR collaborates with researchers across Ontario and around the world to ensure Ontario’s most significant cancer research discoveries have maximum impact for patients and the province’s economy. This report highlights a selection of OICR’s many translational research successes over the last year, including: 

  • An unprecedented investigation into the dark matter of the human cancer genome, which discovered the causes of two thirds of cancers that were previously unexplained;
  • A study that’s bringing next generation genomic sequencing to five Ontario cancer centres, helping match patients to targeted therapies and accelerating cancer research;
  • Developing new software technologies to help bring portable nanopore sequencing into cancer research and care;
  • A pan-Canadian initiative changing the landscape of lung cancer radiotherapy clinical trials and providing more treatment options to patients;
  • The scientific and business excellence of Fusion Pharma Inc., which is developing innovative medical isotopes for treating cancer with reduced side effects.

We hope you enjoy learning more about OICR’s many achievements over the past year and we welcome your feedback at info@oicr.on.ca.

Read the report

September 29, 2017

OICR 2016/17 Annual Report

OICR Annual Report 2016/17

We are pleased to share the Ontario Institute for Cancer Research (OICR) Annual Report for 2016/17.

We are living in an era of unprecedented innovation in cancer research. Recent advances have helped us to better understand cancer and allowed for collaboration on a scale that was previously not possible. This work is happening now and it is happening right here in Ontario.

Continue reading – OICR 2016/17 Annual Report

November 9, 2016

The next generation: Tamara Jamaspishvili

Tamara Jamaspishvili

Men newly diagnosed with prostate cancer face a difficult dilemma: either wait and see how the growth develops and whether it is aggressive, or treat it fully right away and risk the many long-term side effects of treatment. Dr. Tamara Jamaspishvili is a young researcher at Queen’s University in Kingston who is working to change that.

Continue reading – The next generation: Tamara Jamaspishvili

November 1, 2016

From our Annual Report: Improving screening for patients with brain cancer

Lead Researcher

Evaluating new therapies for cancer through clinical trials is one of the most important steps in moving novel drugs from the lab to clinical use. Recently Dr. Michael Taylor and his collaborators discovered a way to improve clinical trials for testing new therapies for medulloblastoma, a common form of brain cancer in children. The study was conducted with OICR’s support.

Continue reading – From our Annual Report: Improving screening for patients with brain cancer

October 19, 2016

From our Annual Report: Personalizing prostate cancer treatment

Dr. Emilie Lalonde

Prostate cancer is the most common cancer in Canadian men and while it has been the focus of extensive research, an estimated 4,000 Canadians die of the disease each year. That is why six years ago Dr. Paul Boutros and Dr. Rob Bristow set out to sequence the normal and diseased tissue of 350 patients and learn from a clinical perspective how genomic information can be used to guide better treatment.

Continue reading – From our Annual Report: Personalizing prostate cancer treatment

October 5, 2016

From our Annual Report: Investing in the cure and the economy

OICR Researcher in the Lab

Ontario has some of the finest cancer researchers in the world who are developing new cancer therapies, diagnostic tools and other anti-cancer technologies. When these novel products make their way into clinical use they improve outcomes for cancer patients and reduce the cancer burden on society.

Continue reading – From our Annual Report: Investing in the cure and the economy

September 27, 2016

Annual report for the Ontario Institute for Cancer Research

OICR Annual Report Cover 2015-16

We are pleased to share with you the 2015-16 annual report for the Ontario Institute for Cancer Research (OICR).

This year’s report describes the world-class research currently underway at the Institute and details our efforts to bring the fruits of this research to patients in partnership with the Fight Against Cancer Innovation Trust. From new techniques to probe cancer genomes to new partnerships for sharing cancer data securely via the cloud, OICR’s innovations have an impact across the province and around the world.

This report also looks forward to our next five years, as we embark on our new Strategic Plan for 2016-2021. We are confident this new plan will lead to continued research success in the future.

Today OICR’s research supports more than 1,700 investigators, clinician scientists, research staff and trainees across the province of Ontario. These researchers, working with collaborators provincially, nationally and internationally, are making a real impact in the fight against cancer.

We hope you enjoy reading about their work. We welcome any feedback you may have at info@oicr.on.ca.

Sincerely,

Mr. Peter Goodhand
Interim President

Dr. Lincoln Stein
Interim Scientific Director